Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
H Hampel, SE O'Bryant, JL Molinuevo… - Nature Reviews …, 2018 - nature.com
Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …
[HTML][HTML] Imaging biomarkers in neurodegeneration: current and future practices
PNE Young, M Estarellas, E Coomans… - Alzheimer's research & …, 2020 - Springer
There is an increasing role for biological markers (biomarkers) in the understanding and
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
[HTML][HTML] Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study
Background Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging
can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods Open …
can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods Open …
[HTML][HTML] Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid-and 18F-FDG-PET imaging
J Ottoy, E Niemantsverdriet, J Verhaeghe… - NeuroImage: Clinical, 2019 - Elsevier
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
[HTML][HTML] Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease
The objective of this study was to evaluate susceptibility changes caused by iron
accumulation in cognitive normal (CN) elderly, those with amnestic mild cognitive …
accumulation in cognitive normal (CN) elderly, those with amnestic mild cognitive …
[HTML][HTML] Focus: the aging brain: amyloid-beta Alzheimer targets—protein processing, lipid rafts, and amyloid-beta pores
M LaFontaine, M Cumbay - The Yale journal of biology and …, 2016 - ncbi.nlm.nih.gov
Amyloid beta (Aβ), the hallmark of Alzheimer's Disease (AD), now appears to be deleterious
in its low number aggregate form as opposed to the macroscopic Aβ fibers historically seen …
in its low number aggregate form as opposed to the macroscopic Aβ fibers historically seen …
Binding Sites of a Positron Emission Tomography Imaging Agent in Alzheimer's β-Amyloid Fibrils Studied Using 19F Solid-State NMR
Amyloid imaging by positron emission tomography (PET) is an important method for
diagnosing neurodegenerative disorders such as Alzheimer's disease. Many 11C-and 18F …
diagnosing neurodegenerative disorders such as Alzheimer's disease. Many 11C-and 18F …
[HTML][HTML] The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
Background There is an urgent need for novel, noninvasive biomarkers to diagnose
Alzheimer's disease (AD) in the predementia stages and to predict the rate of decline …
Alzheimer's disease (AD) in the predementia stages and to predict the rate of decline …
[HTML][HTML] Brain molecular connectivity in neurodegenerative diseases: recent advances and new perspectives using positron emission tomography
Positron emission tomography (PET) represents a unique molecular tool to get in vivo
access to a wide spectrum of biological and neuropathological processes, of crucial …
access to a wide spectrum of biological and neuropathological processes, of crucial …